Notice of Appeal
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]
This appeal hearing will hear appeals against the Final Appraisal Document for the above technology by the following organisations:
- Janssen-Cilag Ltd
- Myeloma UK
The appeal panel will convene on Thursday 27 April 2023 at 10:00am via Zoom to hear oral representations from the appellants.
This page was last updated: